Wound infiltration with 0.25% bupivacaine not effective for postoperative analgesia after cholecystectomy.
The instillation of local anaesthetic agents into surgical wounds has been reported to be an effective method of reducing pain and narcotic requirements, using both local injection and topical application techniques. We performed a double-blind trial to test the value of the long-acting local anaesthetic, bupivacaine, in this role. Eighty patients undergoing elective cholecystectomy were entered into the study. They were divided into 2 groups of 40 patients to compare a local injection technique with a topical application technique. For each route of application, 20 patients received a test solution containing 0.25% plain bupivacaine, and 20 received 0.9% NaCl as a control. Postoperative analgesia in the form of intramuscular pethidine (1-1.5 mg/kg) was made available to all patients on request. The degree of postoperative pain was assessed using three criteria: the time from operation to the first request for analgesia, the total dose of postoperative pethidine required during the first 3 postoperative days and the patient's rating of pain on a 10 cm linear analogue scale at 24 h and 72 h. There was no statistically significant difference between the degree of postoperative pain experienced by patients receiving bupivacaine and those receiving NaCl, when assessed by any criterion. There was also no significant difference found between patients receiving bupivacaine by local infiltration and those receiving the drug topically. It is concluded that the local application of bupivacaine to the wound is not an effective analgesic technique following laparotomy for cholecystectomy.
Adams
W J
WJ
Department of Surgery, Westmead Hospital, New South Wales, Australia.
Avramovic
J
J
Barraclough
B H
BH
D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002045:Bupivacaine / Q000008:administration & dosage / Q000627:therapeutic use*; D002763:Cholecystectomy / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D015552:Injections, Intralesional; D007273:Injections, Intramuscular; D007274:Injections, Intraperitoneal; D007813:Laparotomy / Q000009:adverse effects; D008297:Male; D008614:Meperidine / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D010147:Pain Measurement; D010149:Postoperative Pain / Q000517:prevention & control*
D008614:Meperidine; D002045:Bupivacaine